FDA Okays Another Immunotherapy Plus TKI for Advanced RCC

The FDA has approved avelumab in combination with the tyrosine kinase inhibitor (TKI) axitinib for the first-line treatment of advanced renal cell carcinoma (RCC).
FDA Approvals